ROCKVILLE, Md., Aug. 10,
2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:
RGNX) today announced that it will present at the H.C. Wainwright
2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17th, 2022:
Panel: Unique Delivery Technology Platforms for Better
Compliance and Efficacy
Date: Wednesday, August
17th, 2022
Time: 11:00 a.m. ET
A live webcast of the panel can be accessed in the Investors
section of REGENXBIO's website at www.regenxbio.com. An archived
replay of the webcast will be available in the Investors section of
REGENXBIO's website for approximately 30 days following the
presentation.
About REGENXBIO
Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates,
including late-stage and commercial programs, in multiple
therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to
progress five AAV Therapeutics from our internal pipeline and
licensed programs into pivotal-stage or commercial products by
2025.
Contacts:
Dana
Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-hc-wainwright-2nd-annual-ophthalmology-virtual-conference-301603169.html
SOURCE REGENXBIO Inc.